On a positive note......and God knows we could use that........at least this drug has had a positive effect on PAH patients, and hopefully on all seven of them.  So, it does 'something' that makes a statistical impact on an actual human.  If we can get the same result on Covid patients and on BoM2 patients then bye bye 0.58 cents/share.  The thing is that we may have to wait for some time to find out, and probably quite some time.  

There are a lot of players chasing the Covid silver bullet so it's hard to say if that would necessarily translate into meaningful returns. BoM2 results might not be available until after June 2023 so not sure if those warrants won't also go in the dumpster.  So, if you really believe that this will ultimately prove a hit for patients with CVD then the shares are a bargain now for sure.